Abstract 104P
Background
We evaluated the feasibility of functional magnetic resonance (MR) signature in predicting clinical response to chemotherapy in colorectal liver metastatic (CLM) patients.
Methods
From August 2016 to January 2023, eligible CLM patients were enrolled and functional MR was performed at baseline and one cycle after chemotherapy. The diffusion kurtosis radiomic texture features were extracted and functional MR-imaging signature model was built by the R package called “glmnet” to predict the efficacy of treatment. The initial 100 cases were utilized as training set, the following 48 cases as validation set, and the latter 48 cases as intervention validation set. The primary endpoint was the accuracy of MR-predicted response (ORR) of liver metastases.
Results
The functional MR signature was established and showed a good performance of response prediction (AUC was 0.818 in training cohort and 0.755 in validation cohort). In training set, ORRs were 9.5% (4/42) and 72.4% (42/58) in high-risk and low-risk subgroups. In validation set, the ORRs were 23.81% (5/21) and 74.07% (20/27) in high-risk and low-risk subgroups, respectively (P=0.002). Worse PFS and OS were observed in high-risk population in these two sets. In intervention set, chemotherapy regimen was changed in 22.9% (11/48) patients who were predicted as high-risk by the model, and the ORR reached 54.6 % (6/11), which was higher than that in high-risk subgroups in training and validation set.
Conclusions
Functional MR signature effectively predicts chemotherapy response and long-term survival of patients with CLM, and regimen adjustment guided by the model significantly improve the ORR.
Clinical trial identification
NCT03088163.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract